Oruka Therapeutics, Inc. SC 13D and SC 13D/A reports

Location
855 Oak Grove Ave., Suite 100, Menlo Park, CA
State of incorporation
DE
Fiscal year end
December 31
Data updated at
9/14/2024, 04:09 AM
Form type Sec Links Description Filing date Reporting date
SC 13D/A Report AMENDMENT NO. 1 TO SCHEDULE 13D Sep 13, 2024
SC 13D Report SCHEDULE 13D Sep 6, 2024
SC 13D Report ARCA BIOPHARMA, INC. Apr 5, 2024
SC 13D/A Report AMENDMENT NO. 6 TO THE SCHEDULE 13D Jul 8, 2022
SC 13D/A Report AMENDMENT NO. 5 TO THE SCHEDULE 13D Jun 21, 2022
SC 13D/A Report AMENDMENT NO. 4 TO THE SCHEDULE 13D May 27, 2022
SC 13D/A Report AMENDMENT NO. 3 TO THE SCHEDULE 13D May 11, 2022
SC 13D/A Report AMENDMENT NO. 2 TO THE SCHEDULE 13D Apr 14, 2022
SC 13D/A Report AMENDMENT NO. 1 TO THE SCHEDULE 13D Apr 4, 2022
SC 13D Report THE SCHEDULE 13D Mar 28, 2022
SC 13D/A Report GROWTH EQUITY OPPORTUNITIES FUND IV, LLC --- ARCA BIOPHARMA, INC. - SCHEDULE 13D Mar 5, 2018
SC 13D Report ARCA BIOPHARMA, INC. Jun 29, 2015
SC 13D Report SC 13D Nov 2, 2012